I think no one is talking about the Philippines because it's most likely one patient (at the moment) and a csp is pretty much just an eind equivalent in the US, except we can charge for it(so I heard). Actual EUA or approval will mean much more than a handful of csp/einds. At least for the stock price, for the patients it's great news. Once things hit the bottom line for revenue, then the share price will act accordingly.